Business Context and Reporting Period
This Form 8-K Current Report was filed by Kiora Pharmaceuticals, Inc. (KPRX) on December 13, 2021. The report addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the appointment of David Hollander, MD, MBA, to the Board of Directors on December 13, 2021. Dr. Hollander was appointed to fill a vacancy created by the resignations of two directors in August 2021. He will serve as a Class III director until the 2024 Annual Meeting of Stockholders.
Management Commentary and Governance Details
- Director Profile: Dr. Hollander, age 47, is currently the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. He previously served as Chief Medical Officer of Ora, Inc. and held various leadership roles at Allergan.
- Independence: The Board has determined that Dr. Hollander is independent under the rules of The Nasdaq Capital Market.
- Compensation: As a non-employee director, Dr. Hollander will receive compensation consistent with the Company's other non-employee directors, as detailed in the 2021 Definitive Proxy Statement.
- Related Party Transactions: The filing states there are no arrangements or understandings regarding his appointment, no family relationships with other directors or officers, and no material transactions involving Dr. Hollander exceeding $120,000 since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the independence status of Dr. Hollander against current Nasdaq Capital Market rules.
- Review the 2021 Definitive Proxy Statement (Schedule 14A) to confirm the specific compensation structure for non-employee directors.
- Confirm the status of the two director vacancies that occurred in August 2021 and the timeline for their resolution.
- Check for any subsequent press releases or filings regarding the Company's clinical pipeline or financial status, as this 8-K contains no such data.